Ta'lim fidoyilariKhojiev B.B
Makhmudova L.I
10.5281/zenodo.20512173
Annotatsiya
The triglyceride–glucose (TyG) index is a simple, low-cost surrogate
marker of insulin resistance and has recently emerged as a strong predictor of
metabolic dysfunction-associated fatty liver disease (MAFLD). MAFLD is a highly
prevalent liver disorder closely linked with obesity, type 2 diabetes mellitus, and
metabolic syndrome. Growing evidence suggests that elevated TyG index is
significantly associated with the presence, severity, and progression of MAFLD.
This review summarizes current evidence on the association between TyG index and
MAFLD and highlights its potential role in clinical risk stratification and early
diagnosis.
Kalit so'zlar:
TyG index, MAFLD, insulin resistance, NAFLD, metabolic syndrome, biomarkers.
Foydalanilgan adabiyotlar
1. Ling Q, Chen J, et al. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose–response meta-analysis. Front Endocrinol. 2022. 2. Wang J, Yan S, Cui W, et al. Diagnostic value of TyG index in MAFLD: Systematic review and meta-analysis. Nutrients. 2022. 3. Assaly R, et al. Triglyceride-glucose index and NAFLD risk. Journal of Clinical Medicine. 2022.4. Alharthi J, Eslam M. Biomarkers of metabolic dysfunction-associated fatty liver
disease. J Clin Transl Hepatol. 2022.
5. Tapper EB, Loomba R. Noninvasive assessment of liver fibrosis in metabolic disease.
Nat Rev Gastroenterol Hepatol. 2018.
6. Younossi ZM et al. Global epidemiology of NAFLD and MAFLD transition.
Hepatology. 2020–2021 updates.
7. Lee SH et al. Insulin resistance mechanisms and metabolic disease. Diabetes &
Metabolism Journal. 2021.
8. Eslam M et al. MAFLD definition and clinical implications. Journal of Hepatology.
2020.
